Non-alcoholic fatty liver disease (NAFLD), and the revised term metabolic-(dysfunction) associated fatty liver disease (MAFLD), share key pathophysiological drivers with cardiovascular diseases (CVD), in particular insulin resistance [1]. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.